– USA, CA – Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology (MAST) platform to develop novel therapies for sickle cell disease, heart failure, and stroke, today announced that Matthew Pauls has been appointed to the Company’s Board of Directors, effective immediately.
Mr. Pauls brings more than 20 years of experience in the pharmaceutical industry, including senior leadership roles in a broad spectrum of operational areas and significant experience in new product launches, commercial and technical operations, as well as clinical development, with a specific focus on orphan drug candidates.
“We are delighted to have an executive of Matt’s caliber join our Board, particularly as we near the completion of our Phase 3 ‘EPIC’ study and begin to orient toward product commercialization,” stated Brian M. Culley, Chief Executive Officer. “Matt’s extensive experience and success in commercial strategy and operations, including with therapies for rare diseases, will be a significant asset for Mast.”
Mr. Pauls currently serves as President and Chief Executive Officer and on the board of directors of Strongbridge Biopharma plc (NASDAQ: SBBP), a biopharmaceutical company focused on therapies that target rare diseases. Prior to joining Strongbridge, Mr. Pauls was Chief Commercial Officer of Insmed, Inc., a global biopharmaceutical company focused on rare diseases. Prior to Insmed, Mr. Pauls served as senior vice president, head of global commercial operations at Shire Pharmaceuticals, a global specialty biopharmaceutical company. Earlier in his career, Mr. Pauls also held senior positions at Bristol-Myers Squibb in Brand Management and Payor Marketing, and at Johnson & Johnson in various U.S. and global commercial roles. Mr. Pauls holds B.S. and M.B.A. degrees from Central Michigan University and a J.D. from Michigan State University College of Law.
“I am pleased to join Mast Therapeutics’ Board of Directors at such an exciting time in the Company’s development. I look forward to contributing my experience and helping to further Mast’s efforts to deliver new therapeutic options for serious and life-threatening diseases with significant unmet needs, such as sickle cell disease, heart failure and stroke,” said Mr. Pauls.
About Mast Therapeutics
Mast Therapeutics, Inc. is a publicly traded biopharmaceutical company headquartered in San Diego, California. The Company is leveraging its MAST platform, derived from over two decades of clinical, nonclinical and manufacturing experience with purified and non-purified poloxamers, to develop vepoloxamer (also known as MST-188), its lead product candidate, for serious or life-threatening diseases and conditions typically characterized by impaired microvascular blood flow and damaged cell membranes. The Company is also developing AIR001, a sodium nitrite solution for inhalation via nebulizer, for the treatment of heart failure with preserved ejection fraction (HFpEF).
Vepoloxamer is an investigational new drug being tested in a pivotal Phase 3 study called EPIC for the treatment of vaso-occlusive crisis in patients with sickle cell disease and in a Phase 2 study for the treatment of patients with chronic heart failure. AIR001 is an investigational new drug being tested in two institution-sponsored Phase 2a studies in patients with HFpEF. More information can be found on the Company’s web site at www.masttherapeutics.com. (Twitter: @MastThera)
Mast Therapeutics™ and the corporate logo are trademarks of Mast Therapeutics, Inc.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
